One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
SGLT2 inhibitors protect podocytes in lupus nephritis
Sarah OnuoraÂÂ
doi : 10.1038/s41584-023-01024-1
Volume 19 Issue 10, October 2023
CD38hiCD8+ T cells characterize ICI-mediated arthritis
Robert PhillipsÂÂ
Metal–polyDNA nanoparticles reset the osteoporotic microenvironment
Robert PhillipsÂÂ
PRESTO estimates PsA risk for patients with psoriasis
Robert PhillipsÂ
Fibroblast multiplicity in RA: a synovial state of affairs
Camilla R. L. Machado & Gary S. FiresteinÂ
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?
Bruno FautrelÂÂ
Placebo effects in osteoarthritis: implications for treatment and drug development
Tuhina Neogi & Luana CollocaÂ
Innate immune memory in inflammatory arthritis
Maxime M. Jeljeli & Iannis E. AdamopoulosÂ
Mechanisms and rationale for uricase use in patients with gout
Naomi Schlesinger, Fernando Pérez-Ruiz & Frédéric LiotéÂ
Imaging in inflammatory arthritis: progress towards precision medicine
Ioanna Minopoulou, Arnd Kleyer, Melek Yalcin-Mutlu, Filippo Fagni, Stefan Kemenes, Christian Schmidkonz, Armin Atzinger, Milena Pachowsky, Klaus Engel, Lukas Folle, Frank Roemer, Maximilian Waldner, Maria-Antonietta D’Agostino, Georg Schett & David SimonÂ
Inflammation across tissues: can shared cell biology help design smarter trials?
Tom Hosack, Tom Thomas, Rahul Ravindran, Hans Holm Uhlig, Simon Piers Leigh Travis & Christopher Dominic BuckleyÂ
Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
Kristofer Andréasson, Viggo Hamberg, Jenny Wigén & Gunilla Westergren-ThorssonÂ
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
Janet E. PopeÂÂ
